alemtuzumab
use
induct
agent
renal
transplant
recipi
undergo
live
donor
renal
transplant
donor
kidney
recov
laparoscop
postop
patient
treat
tacrolimu
monotherapi
immunosuppress
wean
possibl
fortyseven
recipi
live
donor
renal
transplant
prior
induct
era
receiv
convent
tripl
drug
immunosuppress
without
antibodi
induct
serv
histor
control
mean
followup
day
alemtuzumab
group
day
histor
control
group
actuari
patient
graft
surviv
alemtuzumab
group
compar
control
group
respect
incid
acut
cellular
reject
acr
year
alemtuzumab
group
p
histor
control
group
episod
acr
alemtuzumab
group
banff
b
sensit
steroid
puls
treatment
reject
cytomegaloviru
diseas
infect
incid
delay
graft
function
incid
posttranspl
insulindepend
diabet
mellitu
studi
repres
largest
seri
date
live
donor
renal
transplant
recipi
undergo
alemtuzumab
induct
confirm
shortterm
safeti
efficaci
approach
alemtuzumab
human
igg
monoclon
antibodi
associ
prolong
deplet
cell
peripher
circul
system
administr
b
cell
natur
killer
cell
monocyt
also
deplet
alemtuzumab
lesser
extent
food
drug
administr
fda
initi
approv
treatment
chronic
bcell
lymphocyt
leukemia
abil
alemtuzumab
deplet
lymphocyt
circul
gener
interest
use
antibodi
solid
organ
transplant
alemtuzumab
approv
fda
use
organ
transplant
experi
monoclon
antibodi
renal
transplant
promis
implement
immunosuppress
regimen
base
two
key
principl
recipi
pretranspl
lymphoid
deplet
minim
use
posttranspl
steroidfre
immunosuppress
immunosuppress
regimen
base
principl
intend
deplet
preoper
preexist
alloreact
donorspecif
cell
prevent
acut
reject
minim
postop
immunosuppress
calcineurin
inhibitor
cni
permit
interact
donor
recipi
leukocyt
previous
observ
use
precondit
permit
space
wean
immunosuppress
use
alemtuzumab
compar
thymoglobulin
associ
substanti
lower
incid
acut
cellular
reject
acr
associ
low
incid
infecti
complic
advers
event
present
largest
seri
date
live
donor
renal
transplant
perform
alemtuzumab
induct
tacrolimu
monotherapi
januari
decemb
total
consecut
laparoscop
live
donor
nephrectomi
result
live
donor
renal
transplant
kidneyonli
recipi
two
retranspl
perform
univers
pittsburgh
medic
center
starzl
transplant
institut
upmc
sti
fortysix
live
donor
kidney
recipi
previou
extraren
solid
organ
transplant
n
posit
pretranspl
crossmatch
n
exclud
prospect
data
collect
donor
recipi
immunosuppress
regimen
base
upon
pretreat
intraven
mg
alemtuzumab
berlex
seattl
wa
usa
premed
g
methylprednisolon
repeat
prior
reperfus
avoid
intraop
hypotens
cytokin
releas
syndrom
posttransplant
lowdos
tacrolimu
monotherapi
target
trough
ngml
first
day
posttransplant
given
start
postop
day
approxim
day
posttransplant
twicedaili
dose
tacrolimu
consolid
day
recipi
clinic
evid
acr
ie
increas
creatinin
confirm
biopsi
protocol
biopsi
perform
patient
continu
well
dose
wean
everi
day
anoth
month
wean
continu
three
time
week
twice
week
week
month
interv
patient
continu
well
absenc
rise
creatinin
clinic
acr
episod
biopsyproven
acr
treat
g
intraven
methylprednisolon
mg
intraven
steroidresist
acr
protocol
approv
upmc
innov
practic
committe
upmc
pharmaci
therapeut
committe
previous
describ
data
analysi
approv
univers
pittsburgh
institut
review
board
histor
control
group
retrospect
data
live
donor
renal
transplant
perform
march
juli
upmc
sti
prior
thymoglobulin
alemtuzumab
induct
era
exclud
recipi
previou
extraren
solid
organ
transplant
posit
pretranspl
crossmatch
recipi
receiv
induct
therapi
collect
recipi
receiv
induct
therapi
treat
tripl
convent
immunosuppress
consist
tacrolimu
prednison
mycophenol
mofetil
baselin
demograph
laboratori
factor
describ
mean
deviat
continu
variabl
frequenc
distribut
dichotom
variabl
fisher
exact
use
compar
differ
acr
human
leukocyt
antigen
hla
mismatch
panel
reactiv
antibodi
pra
creatinin
statist
signific
differ
group
test
use
twosampl
ttest
analysi
varianc
anova
continu
variabl
chi
squar
test
categor
variabl
actuari
recipi
graft
surviv
calcul
begin
time
transplant
kidney
graft
failur
defin
death
recipi
remov
allograft
loss
function
requir
return
dialysi
actuari
kaplanmei
surviv
calcul
use
statist
packag
social
scienc
spss
softwar
seri
follow
decemb
magnitud
factor
associ
surviv
estim
breslow
gener
wilcoxon
statist
test
null
hypothesi
associ
factor
surviv
present
cumul
recipi
graft
surviv
curv
use
kaplanmei
method
statist
test
twotail
statist
signific
defin
p
mean
followup
live
donor
renal
transplant
recipi
receiv
alemtuzumab
induct
day
recipi
previou
fail
transplant
eighteen
recipi
recipi
transplant
hiv
pediatr
african
american
recipi
averag
hla
mismatch
recipi
pretranspl
pra
see
tabl
detail
recipi
characterist
comparison
none
patient
histor
control
group
hiv
time
transplant
histor
control
group
hla
match
mean
hla
mismatch
hla
p
hla
b
p
hla
dr
p
pretranspl
pra
p
alemtuzumab
group
mean
followup
histor
control
group
day
actuari
recipi
surviv
group
receiv
alemtuzumab
induct
p
histor
control
group
respect
see
figur
recipi
surviv
group
receiv
alemtuzumab
induct
day
mean
followup
four
death
group
day
posttransplant
three
excel
graft
function
time
death
two
death
relat
iatrogen
caus
one
patient
die
sepsi
secondari
bowel
perfor
allograft
nephrectomi
outsid
institut
allograft
failur
biopsyproven
recurr
focal
segment
glomerulosclerosi
fsg
anoth
patient
die
sepsi
function
allograft
suffer
esophag
perfor
esophagogastroduodenoscopi
egd
immunosuppress
discontinu
sepsi
death
myocardi
infarct
month
posttransplant
nonsmal
cell
lung
cancer
month
posttransplant
respect
two
late
death
day
posttransplant
account
drop
tail
end
actuari
recipi
graft
surviv
curv
see
figur
b
recipi
followup
time
day
howev
strongli
caution
acut
drop
tail
end
may
also
repres
seriou
longterm
concern
clearli
longterm
followup
requir
demonstr
actuari
graft
surviv
alemtuzumab
histor
control
group
respect
see
figur
tabl
statist
signific
p
alemtuzumab
group
tend
improv
graft
surviv
total
nine
renal
allograft
loss
followup
day
posttransplant
incid
delay
graft
function
dgf
patient
alemtuzumab
histor
control
group
function
graft
mean
creatinin
year
mgdl
mgdl
p
respect
see
tabl
mean
day
followup
mean
creatinin
mgdl
mgdl
alemtuzumab
histor
control
group
respect
mean
day
followup
patient
receiv
alemtuzumab
induct
recipi
daili
bid
qd
tacrolimu
monotherapi
recipi
wean
spaceddos
monotherapi
recipi
multiimmunosuppress
drug
therapi
combin
mycophenol
mofetil
prednison
rapamun
ad
tacrolimu
monotherapi
episod
acr
see
tabl
hla
mismatch
patient
receiv
alemtuzumab
induct
daili
twice
daili
bid
daili
qd
tacrolimu
monotherapi
versu
spaceddos
monotherapi
vs
p
import
protocol
day
mean
followup
recipi
still
complet
steroidfre
sinc
time
transplant
frequenc
immunosuppress
dose
recipi
receiv
tacrolimu
monotherapi
present
tabl
recipi
wean
spaceddos
monotherapi
recipi
everi
day
qod
recipi
three
time
per
week
recipi
twice
per
week
recipi
per
week
tacrolimu
total
six
recipi
hla
ident
donor
frequenc
tacrolimu
dose
follow
see
tabl
bid
n
qod
n
week
n
n
alemtuzumab
induct
recipi
month
followup
major
recipi
n
spaceddos
monotherapi
anticip
number
recipi
spaceddos
monotherapi
continu
increas
time
alemtuzumab
group
cumul
incid
acr
month
mean
followup
day
n
n
n
n
n
n
n
respect
histor
control
group
cumul
incid
acr
month
day
p
p
p
p
p
p
p
respect
see
tabl
number
recipi
recurr
episod
acr
alemtuzumab
versu
histor
control
group
versu
tabl
detail
characterist
alemtuzumab
recipi
episod
acr
presenc
graft
failur
episod
sever
time
treatment
acr
alemtuzumab
group
also
depict
tabl
alemtuzumab
patient
acr
lost
renal
allograft
patient
immunosuppress
reduc
secondari
bk
nephropathi
subsequ
acr
patient
die
myocardi
infarct
result
graft
loss
patient
die
sepsi
secondari
esophag
perfor
egd
immunosuppress
withdrawn
result
allograft
loss
banff
acr
patient
acr
day
posttransplant
one
patient
antibodymedi
reject
amr
evid
posit
diffus
peritubular
donorspecif
antibodi
dsa
identif
titer
patient
respond
plasmapheresi
intraven
immunoglobulin
ivig
resolut
dsa
titer
recipi
receiv
alemtuzumab
induct
wean
mainten
immunosuppress
experienc
prewean
acr
acr
prior
wean
immunosuppress
anoth
patient
develop
acr
wean
daili
monotherapi
postwean
acr
see
tabl
total
episod
biopsyproven
acr
alemtuzumab
recipi
acr
see
tabl
episod
acr
banff
b
sensit
steroid
puls
treatment
reject
banff
banff
acr
episod
anoth
four
acr
episod
grade
banff
one
grade
banff
one
episod
banff
reject
banff
acr
treat
singl
dose
mg
alemtuzumab
intraven
episod
biopsyproven
acr
histor
control
recipi
acr
see
tabl
fiftyeight
percent
total
six
recipi
hla
ident
donor
alemtuzumab
group
episod
acr
hla
ident
recipi
incid
acr
appear
higher
african
american
year
p
day
followup
one
african
american
acr
noncompli
followup
recipi
cytomegaloviru
cmv
diseas
infect
cmv
diseas
defin
presenc
sign
symptom
tissu
injuri
isol
viru
andor
histopatholog
immunohistochem
evid
cmv
cmv
infect
defin
isol
viru
detect
viral
protein
nucleic
acid
bodi
fluid
tissu
specimen
recipi
receiv
prophylact
valganciclovir
month
three
recipi
develop
bk
nephropathi
treat
wean
immunosuppress
cidofivir
one
three
bk
nephropathi
recipi
eventu
lost
renal
allograft
posttranspl
lymphoprolif
diseas
ptld
group
receiv
alemtuzumab
induct
incid
recurr
fsg
alemtuzumab
group
recipi
diabet
prior
transplant
one
patient
develop
new
onset
insulindepend
diabet
mellitu
posttranspl
twenti
percent
recipi
pretranspl
fast
glucos
mgdl
histor
control
recipi
pretranspl
diabet
nephropathi
develop
insulindepend
diabet
mellitu
posttransplant
alemtuzumab
induct
one
vascular
thrombosi
occur
seri
relat
traumat
transect
renal
vein
arteri
hilum
recipi
woke
despit
vascular
repair
ureter
stenosi
occur
one
patient
hiv
recipi
stenosi
revis
ureteroureter
anastomosi
nativ
uret
recipi
continu
excel
graft
function
also
appear
higher
incid
pulmonari
toxic
vast
major
recipi
extub
posttransplant
requir
intens
care
unit
neutropenia
treat
subcutan
inject
neupogen
filgrastim
amgen
inc
thousand
oak
ca
usa
outpati
basi
total
episod
neutropenia
requir
neupogen
recipi
recipi
receiv
neupogen
dose
subcutan
neupogen
cost
incid
readmiss
hospit
reason
within
first
month
posttranspl
common
reason
urinari
tract
infect
dehydr
rise
serum
creatinin
need
exclud
acr
report
repres
largest
seri
date
live
donor
renal
transplant
recipi
receiv
alemtuzumab
induct
confirm
shortterm
safeti
efficaci
drug
induct
agent
despit
complex
recipi
popul
includ
retranspl
transplant
transplant
hiv
recipi
pediatr
recipi
incid
acr
year
actuari
patient
graft
surviv
respect
shortterm
surviv
superior
us
transplantscientif
registri
transplant
recipi
srtr
databas
year
unadjust
patient
graft
surviv
respect
furthermor
good
graft
function
also
observ
mean
creatinin
mgdl
year
mgdl
mean
day
followup
group
receiv
alemtuzumab
induct
significantli
lower
incid
acr
histor
control
year
p
importantli
incid
recipi
complic
year
includ
ptld
cmv
diseas
infect
posttranspl
insulindepend
diabet
mellitu
except
low
find
support
extend
caln
colleagu
first
employ
alemtuzumab
induct
therapi
renal
transplant
follow
lowdos
cyclosporin
monotherapi
initi
result
patient
promis
prompt
trial
studi
use
alemtuzumab
induct
agent
renal
transplant
followup
studi
compar
outcom
renal
transplant
recipi
receiv
alemtuzumab
induct
therapi
follow
lowdos
cyclosporin
monotherapi
renal
transplant
contemporan
control
recipi
receiv
convent
immunosuppress
consist
cyclosporin
azathioprin
prednisolon
patient
alemtuzumab
group
experienc
acr
beyond
posttranspl
compar
none
control
group
incid
acr
similar
year
alemtuzumab
group
vs
control
group
overal
patient
vs
graft
vs
surviv
rate
well
incid
infecti
complic
similar
alemtuzumab
control
group
respect
conclud
alemtuzumab
allow
satisfactori
longterm
patient
graft
surviv
equival
seen
standard
tripl
immunosuppress
avoid
steroid
therapi
addit
sever
recent
studi
demonstr
alemtuzumab
effect
induct
agent
live
donor
deceas
donor
renal
transplant
shortterm
side
effect
knechtl
colleagu
univers
wisconsin
util
alemtuzumab
induct
therapi
follow
sirolimu
monotherapi
pilot
studi
involv
renal
transplant
recipi
month
followup
studi
infecti
complic
evid
malign
howev
patient
experienc
reject
reject
treat
success
patient
patient
experienc
graft
loss
eight
patient
experienc
reject
five
evid
receiv
alemtuzumab
experienc
significantli
humor
reject
recent
knechtl
colleagu
report
result
renal
allograft
recipi
receiv
alemtuzumab
induct
therapi
compar
recipi
receiv
either
antibodi
thymoglobulin
induct
therapi
cni
mycophenol
mofetil
prednison
mainten
group
receiv
alemtuzumab
experienc
significantli
lower
incid
acr
compar
group
rate
infect
malign
significantli
differ
importantli
patient
dgf
experienc
less
reject
alemtuzumab
control
group
improv
graft
surviv
kaufman
colleagu
report
similar
result
kidney
transplant
patient
receiv
alemtuzumab
n
basiliximab
n
induct
prednisonefre
mainten
protocol
use
tacrolimu
ngml
mycophenol
mofetil
combin
lower
rate
earli
month
acr
observ
alemtuzumab
versu
basiliximab
group
actual
acr
rate
group
live
donor
recipi
equival
year
alemtuzumab
basiliximab
actual
recipi
graft
surviv
among
live
donor
recipi
treat
alemtuzumab
respect
kirk
et
al
report
seven
nonsensit
recipi
live
donor
kidney
treat
periop
alemtuzumab
follow
postop
without
mainten
immunosuppress
recipi
develop
revers
acr
within
first
month
character
predominantli
monocyt
infiltr
episod
respons
treatment
steroid
sirolimu
recent
pilot
studi
five
recipi
live
donor
kidney
treat
periop
alemtuzumab
deoxyspergualin
inhibitori
effect
monocyt
macrophag
without
mainten
immunosuppress
kirk
et
al
report
five
recipi
develop
revers
acr
similar
time
histolog
transcript
profil
seen
patient
treat
alemtuzumab
alon
tcell
deplet
combin
deoxyspergualin
induc
toler
nonhuman
primat
appear
induc
toler
human
appear
chemokin
product
adequ
suppress
alemtuzumab
induct
form
mainten
immunosuppress
requir
protocol
pilot
studi
kidney
transplant
recipi
receiv
alemtuzumab
induct
sirolimu
mycophenol
mofetil
mainten
without
cni
steroid
demonstr
rel
high
incid
acr
year
possibl
pulmonari
toxic
rais
concern
efficaci
safeti
protocol
studi
point
import
least
initi
period
cni
recipi
receiv
alemtuzumab
induct
see
higher
incid
pulmonari
toxic
vast
major
recipi
extub
posttransplant
requir
intens
care
unit
recent
random
control
clinic
trial
compar
thymoglobulin
n
alemtuzumab
n
daclizumab
n
deceas
donor
renal
transplant
recipi
induct
therapi
alemtuzumab
tacrolimu
trough
ngml
mycophenol
mofetil
g
daili
combin
mainten
therapi
associ
similar
actuari
patient
graft
surviv
function
thymoglobulin
creatinin
clearanc
alemtuzumab
creatinin
clearanc
daclizumab
creatinin
clearanc
respect
major
patient
remain
steroidfre
year
posttransplant
addit
encourag
excel
preliminari
result
also
obtain
alemtuzumab
induct
hiv
recipi
pediatr
recipi
alemtuzumab
deplet
tand
b
lymphocyt
peripher
circul
effect
monocyt
less
pronounc
plasma
cell
effect
deplet
circul
accordingli
recent
report
describ
monocytepredomin
acr
well
sever
earli
acut
humor
reject
see
higher
incid
earli
sever
acut
humor
reject
patient
tacrolimu
monotherapi
import
cni
requir
earli
posttranspl
period
alemtuzumab
induct
demonstr
pilot
studi
flechner
knechtl
et
al
major
acr
episod
current
studi
banff
success
treat
steroid
bolu
find
report
sever
limit
studi
confirm
shortterm
safeti
efficaci
alemtuzumab
longterm
followup
clearli
need
mean
followup
day
recipi
rel
short
acut
drop
tail
end
kaplanmei
patient
graft
surviv
curv
may
relat
small
number
patient
longterm
followup
howev
may
also
repres
seriou
longterm
concern
care
assess
graft
function
creatinin
clearanc
variou
time
point
may
provid
accur
measur
renal
function
continu
followup
clearli
requir
assess
longterm
graft
surviv
function
delay
incid
acr
occur
lymphocyt
return
baselin
need
monitor
close
rate
late
chronic
allograft
nephropathi
repopul
profound
deplet
peripher
blood
lymphocyt
monocyt
nk
cell
alemtuzumab
take
year
knechtl
colleagu
found
lymphocyt
reach
least
baselin
valu
month
postalemtuzumab
induct
also
hope
lower
start
dose
tacrolimu
progress
wean
time
decreas
incid
cni
nephrotox
observ
compar
tradit
tripl
immunosuppress
longterm
benefit
alemtuzumab
induct
tacrolimu
monotherapi
clearli
warrant
investig
immunolog
mechan
permit
abil
wean
immunosuppress
patient
yet
elucid
addit
studi
direct
elucid
mechan
current
way
hope
monitor
class
ii
antibodi
enzymelink
immunoassay
identif
dsa
potenti
aid
wean
immunosuppress
thu
decreas
incid
postwean
acr
also
process
assess
frequenc
function
donorreact
cell
well
identifi
cytokin
gene
polymorph
assay
alloantibodi
titer
recipi
experienc
reject
spaceddos
wean
advis
empir
immunosuppress
withdraw
otherwis
stabl
patient
remain
establish
given
increas
albeit
low
rate
acut
reject
seen
postwean
previous
stabl
patient
approach
remain
investig
wean
time
day
wean
tacrolimu
monotherapi
consolid
daili
dose
less
eg
qd
amr
antibodymedi
reject
evid
dsa
donor
specif
antibodi
pt
underw
plasmapheresi
ivig
mm
hla
mismatch
b
dr
loci
solu
solumedrol
puls
thymo
thymoglobulin
pp
plasmapheresi
campath
mg
one
continu
episod
acr
resolut
solumedrol
ye
immuno
pt
die
sepsi
secondari
esophag
perfor
egd
immunosuppress
withdrawn
result
loss
allograft
acr
j
transplant
author
manuscript
avail
pmc
august
